Quetiapine Fumarate Tablet
Product Images NDC 70518-1919

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Quetiapine Fumarate (NDC 70518-1919). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

35b3883e Bd69 43d5 8f5a 254dd92cd528 1584 1

Quetiapine fumarate 300 mg oral tablets label by RemedyRepack Inc. The white circular tablet has a score line on one side and an imprint showing the number 108 on the other side. It is a prescription medication identified by NDC 70518-1919.*

FDA Label Image

9fb56acd 2611 4c7d B63f 1de0c57383ea 1628 1

Quetiapine fumarate 300 mg oral tablets are shown in a white plastic bottle with a white child-resistant cap. The label features the REMEDYREPACK INC. logo and includes dosage strength and drug name information prominently in black and white text. The bottle appears to contain 100 tablets.*

FDA Label Image

Remedy_label (Remedy Label)

Quetiapine Tablet 300 mg oral tablets packaging label, showing a quantity of 30 tablets. The label includes the NDC number 70518-1919-01, and is repackaged by RemedyRepack Inc., Indiana, PA. Storage instructions and a QR code are also visible on the label.*

FDA Label Image

A644051f 21f4 4c76 9ed2 E96417d77df9 01

Chemical structure diagram of the active ingredient quetiapine fumarate, showing molecular components and connectivity including rings, nitrogen, oxygen, sulfur atoms, and functional groups.*

FDA Label Image

A644051f 21f4 4c76 9ed2 E96417d77df9 02

A Kaplan-Meier survival curve chart showing the proportion of patients with relapse (%) on the y-axis over time in weeks on the x-axis. Two groups are compared: QTP+LI/VAL (dashed line) and PLA+LI/VAL (solid line), illustrating relapse rates over a span of 100 weeks.*

FDA Label Image

A644051f 21f4 4c76 9ed2 E96417d77df9 03

A Kaplan-Meier survival curve chart depicting the proportion of patients with relapse (%) over time in weeks up to 100 weeks. The chart compares two groups: one treated with quetiapine fumarate plus lithium/valproate (dashed line) and the other with placebo plus lithium/valproate (solid line). The chart shows relapse proportions increasing over time for both groups, with the placebo group having a higher relapse proportion.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.